Absorica Ld (Isotretinoin, Micronized) Patent Expiration, LOE Window & CMS Spending

Absorica Ld (Isotretinoin, Micronized) by Sun Pharmaceutical: FDA Orange Book LOE 2035-08-04, 13 AB generics, $5.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSun Pharmaceutical
FDA Application & PathwayN211913 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2035-08-04
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors13
2024 CMS Total Public Spend$5.8M
2024 Medicare Part D Spend$23K
2024 Medicaid Spend$5.8M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel